DSGN — Design Therapeutics Inc

Design Therapeutics Inc (DSGN) is a biotechnology company listed on NASDAQ. It is led by Pratik Shah Ph.D., based in 6005 Hidden Valley Road, Carlsbad, CA, United States, 92011, with about 56 employees. Design Therapeutics, Inc. a clinical-stage biopharmaceutical company, research, designs, develops, and commercializes small molecule therapeutic drugs for the treatment of genetic diseases in the United States. The company utilizes its GeneTAC platform to design and develop therapeutic candidates for inherited diseases caused by nucleotide repeat expansion. Its lead product candidates for potentially disease-modifying treatment comprises Friedreich Ataxia, a monogenic, autosomal recessive, progressive multi-system disease that affects organ systems dependent on mitochondrial function that brings to neurological, cardiac, and metabolic dysfunction; Myotonic Dystrophy Type-1, a dominantly-inherited, monogenic progressive neuromuscular disease affecting skeletal muscle, heart, brain, and other organs; Fuchs Endothelial Corneal Dystrophy, a genetic eye disease characterized by bilateral degeneration of corneal endothelial cells and progressive loss of vision; and Huntington's Disease, a dominantly inherited, monogenic neurodegenerative disease characterized by movement, cognitive, and psychiatric disorders. Design Therapeutics, Inc. was incorporated in 2017 and is headquartered in Carlsbad, California.

Latest reported DSGN revenue for 2025-09-30 was $0. Net income was -$53.8M. DSGN currently screens at market cap $214.0M.

Use this DSGN page for company research — sector, financials, and the latest filing takeaway — not a live tape. The session quote (last, range, volume) lives on the DSGN quote page. Cached 10-K, 10-Q, 8-K, and Form 4 exhibits are on the DSGN SEC filings page. Lician reads the product cache first so this HTML stays unique to Design Therapeutics Inc even when a live quote feed is slow.